Ksq Therapeutics, Inc.

Pandion Operations, Inc.

Micah Benson

Michael R Schlabach

Gregory V Kryukov

Jason J Merkin

Noah Jacob Tubo

Solomon Martin Shenker

James Martin Kaberna, Ii

Joanne Louise Viney

Nathan Higginson-Scott

Alan Crane

The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.

Gene-regulating compositions and methods for improved immunotherapy

This invention describes a novel CRISPR/Castarget identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.

Methods for screening for cancer targets

This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.

Methods and compounds for conferring site-specific or local immune privilege.

Growing community of inventors

Cambridge, MA, United States of America

Micah Benson